Methods for screening for binding partners of G-protein coupled receptors

Patent metadata

Field	Value
Publication number	US-9260505-B2
Application number	US-201414255939-A
Country	US
Kind code	B2
Filing date	Apr 17, 2014
Priority date	Dec 20, 2007
Publication date	Feb 16, 2016
Grant date	Feb 16, 2016

Abstract

A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular formation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed.

First claim

The invention claimed is:

1. A biosensor comprising a mutant GPCR of a parent GPCR, wherein the mutant GPCR is able to bind to the same ligand as the parent GPCR and which has increased stability in a particular conformation relative to the parent GPCR in the same particular conformation under denaturing conditions, which stability in a particular conformation can be determined by measuring denaturation as manifest by loss of ligand binding ability, and wherein when a target substance binds to said mutant GPCR, a detectable signal is produced.

2. A biosensor according to claim 1 , wherein the mutant GPCR is provided by:
(a) providing one or more mutants of a parent GPCR,
(b) selecting a ligand, the ligand being one which binds to the parent GPCR when the GPCR is residing in a particular conformation,
(c) determining whether the or each mutant GPCR has increased stability with respect to binding the selected ligand compared to the stability of the parent GPCR with respect to binding that ligand, and
(d) selecting a mutant that has an increased stability compared to the parent GPCR with respect to binding the selected ligand.

3. A biosensor according to claim 2 , wherein the mutant GPCR provided in step (a) is any one of a β-adrenergic receptor, an adenosine receptor, a neurotensin receptor or a muscarinic.

4. A biosensor according to claim 1 , wherein the detectable signal is any of a change in colour; fluorescence; evanescence; surface plasmon resonance; electrical conductance or charge separation; ultraviolet; visible or infrared absorption; luminescence; chemiluminescence; electrochemiluminescence; fluorescence anisotropy; fluorescence intensity; fluorescence lifetime; fluorescence polarisation; fluorescence energy transfer; molecular mass; electron spin resonance; nuclear magnetic resonance; hydrodynamic volume or radius; specific gravity; scintillation; field effect resistance; electrical impedance; acoustic impedance; quantum evanescence; resonant scattering; fluorescent quenching; fluorescence correlation spectroscopy; acoustic load; acoustic shear wave velocity; binding force; or interfacial stress.

5. A biosensor according to claim 1 wherein the biosensor is a flow-based biosensor, selected from the group consisting of a quartz crystal microbalance biosensor, an evanescent wave biosensor, a planar wave guide biosensor, a surface Raman sensor, and a surface plasmon resonance biosensor.

6. A biosensor according to claim 1 , wherein the target substance is any of a molecule, a biomolecule, a peptide, a protein, a carbohydrate, a lipid, a GPCR ligand, a synthetic molecule, a drug, a drug metabolite or a disease biomarker.

7. A biosensor according to claim 1 , wherein the mutant GPCR is a Class 1 or a Class 2 GPCR.

8. A biosensor according to claim 1 , wherein the mutant GPCR is a human GPCR.

9. A biosensor according to claim 1 , wherein the biosensor is in a chip or a bead supported form.

10. The biosensor of claim 1 , wherein the mutant GPCR has increased thermo stability.

11. The biosensor of claim 1 , wherein the mutant GPCR is expressed in Escherichia coli.

12. A method of producing a biosensor comprising a mutant GPCR of a parent GPCR, wherein the mutant GPCR is one that is able to bind to the same ligand as the parent GPCR and which has increased stability in a particular conformation relative to the parent GPCR in the same particular conformation under denaturing conditions, which stability in a particular conformation can be determined by measuring denaturation as manifest by loss of ligand binding ability, and wherein when a target substance binds to said mutant GPCR, a detectable signal is produced, the method comprising:
(a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; and
(b) immobilising the mutant GPCR onto a solid support for incorporation into a biosensor.

13. A method according to claim 12 , wherein providing the mutant GPCR of step (a) comprises:
(i) providing one or more mutants of a parent GPCR,
(ii) selecting a ligand of a particular class, the ligand being one which binds to the parent GPCR when the GPCR is residing in a particular conformation, wherein an agonist ligand is used to select for one or more mutants with increased conformational stability in the agonist conformation by binding to the one or more mutants; and an antagonist ligand is used to select for one or more mutants with increased conformational stability in the antagonist conformation by binding to the one or more mutants,
(iii) determining whether the or each mutant GPCR has increased conformational stability with respect to binding the selected ligand compared to the conformational stability of the parent GPCR with respect to binding that ligand, by measuring denaturation as manifest by loss of ligand binding under denaturing conditions selected from the group consisting of heat, a detergent, a chaotropic agent and an extreme of pH, and
(iv) selecting those mutants that have an increased conformational stability compared to the parent GPCR with respect to binding the selected ligand; wherein if the selected ligand in step (ii) is an agonist ligand, then the particular conformation in which the GPCR resides in step (iii) is an agonist conformation, and if the selected ligand in step (ii) is an antagonist ligand, then the particular conformation in which the GPCR resides in step (iii) is an antagonist conformation.

14. A method according to claim 13 wherein the one or more mutants are brought into contact with the selected ligand prior to step (iii); or wherein the one or more mutants are provided in a solubilised form; or wherein the binding affinity of the mutant for the selected ligand is substantially the same or greater than the binding affinity of the parent for the selected ligand; or wherein the method is repeated for one or more rounds, with the selected mutants having increased stability in step (i) representing the parent GPCR in a subsequent round of the method; or wherein a mutant GPCR is selected which has increased stability to more than one of heat, a detergent, a chaotropic agent and an extreme of pH; or wherein the ligand is any one of a full agonist, a partial agonist, an inverse agonist, an antagonist; or wherein the ligand is a polypeptide which binds to the GPCR selected from the group consisting of an antibody, an ankyrin, a G protein, an RGS protein, an arrestin, a GPCR kinase, a receptor tyrosine kinase, a RAMP, a NSF, a GPCR, an NMDA receptor subunit NR1 or NR2a, and calcyon, a fibronectin domain framework, or a fragment or derivative thereof that binds to the GPCR; or wherein in step (ii) two or more ligands are selected, the presence of each causes the GPCR to reside in the same particular conformation; or wherein a mutant GPCR is selected which has reduced ability to bind a ligand of a different class to the ligand selected in step (ii) compared to its parent; or wherein the GPCR is any one of a β-adrenergic receptor, an adenosine receptor and a neurotensin receptor.

15. A method according to claim 13 , wherein providing the mutant GPCR of step (a) further comprises:
(i) identifying the position or positions of the mutated amino acid residue or residues in the mutant GPCR or GPCRs which has been selected for increased conformational stability, and
(ii) synthesising a mutant GPCR which contains a replacement amino acid at one or more of the positions identified.

16. The method of claim 13 , wherein denaturation as manifest by loss of ligand binding is measured under the d

Assignees

• Heptares Therapeutics Ltd

Inventors

• Weir Malcolm Peter
• Marshall Fiona Hamilton

Classifications

• C07K14/70571 Primary

  for neuromediators, e.g. serotonin receptor, dopamine receptor · CPC title

• G01N33/54366

  Apparatus specially adapted for solid-phase testing · CPC title

• C07K14/705 Primary

  Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} · CPC title

• G01N2500/00

  Screening for compounds of potential therapeutic value · CPC title

• G01N2333/726

  G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH · CPC title